These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 31294695)

  • 1. The CUL5 ubiquitin ligase complex mediates resistance to CDK9 and MCL1 inhibitors in lung cancer cells.
    Kabir S; Cidado J; Andersen C; Dick C; Lin PC; Mitros T; Ma H; Baik SH; Belmonte MA; Drew L; Corn JE
    Elife; 2019 Jul; 8():. PubMed ID: 31294695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neddylation E2 UBE2F Promotes the Survival of Lung Cancer Cells by Activating CRL5 to Degrade NOXA via the K11 Linkage.
    Zhou W; Xu J; Li H; Xu M; Chen ZJ; Wei W; Pan Z; Sun Y
    Clin Cancer Res; 2017 Feb; 23(4):1104-1116. PubMed ID: 27591266
    [No Abstract]   [Full Text] [Related]  

  • 3. MARCH5 mediates NOXA-dependent MCL1 degradation driven by kinase inhibitors and integrated stress response activation.
    Arai S; Varkaris A; Nouri M; Chen S; Xie L; Balk SP
    Elife; 2020 Jun; 9():. PubMed ID: 32484436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of MARCH5 ubiquitin ligase abrogates MCL1-dependent resistance to BH3 mimetics via NOXA.
    Subramanian A; Andronache A; Li YC; Wade M
    Oncotarget; 2016 Mar; 7(13):15986-6002. PubMed ID: 26910119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploiting MCL1 Dependency with Combination MEK + MCL1 Inhibitors Leads to Induction of Apoptosis and Tumor Regression in
    Nangia V; Siddiqui FM; Caenepeel S; Timonina D; Bilton SJ; Phan N; Gomez-Caraballo M; Archibald HL; Li C; Fraser C; Rigas D; Vajda K; Ferris LA; Lanuti M; Wright CD; Raskin KA; Cahill DP; Shin JH; Keyes C; Sequist LV; Piotrowska Z; Farago AF; Azzoli CG; Gainor JF; Sarosiek KA; Brown SP; Coxon A; Benes CH; Hughes PE; Hata AN
    Cancer Discov; 2018 Dec; 8(12):1598-1613. PubMed ID: 30254092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Confounding off-target effects of BH3 mimetics at commonly used concentrations: MIM1, UMI-77, and A-1210477.
    Mallick DJ; Soderquist RS; Bates D; Eastman A
    Cell Death Dis; 2019 Feb; 10(3):185. PubMed ID: 30796196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The anti-apoptotic protein BCL2L1/Bcl-xL is neutralized by pro-apoptotic PMAIP1/Noxa in neuroblastoma, thereby determining bortezomib sensitivity independent of prosurvival MCL1 expression.
    Hagenbuchner J; Ausserlechner MJ; Porto V; David R; Meister B; Bodner M; Villunger A; Geiger K; Obexer P
    J Biol Chem; 2010 Mar; 285(10):6904-12. PubMed ID: 20051518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pooled Genomic Screens Identify Anti-apoptotic Genes as Targetable Mediators of Chemotherapy Resistance in Ovarian Cancer.
    Stover EH; Baco MB; Cohen O; Li YY; Christie EL; Bagul M; Goodale A; Lee Y; Pantel S; Rees MG; Wei G; Presser AG; Gelbard MK; Zhang W; Zervantonakis IK; Bhola PD; Ryan J; Guerriero JL; Montero J; Liang FJ; Cherniack AD; Piccioni F; Matulonis UA; Bowtell DDL; Sarosiek KA; Letai A; Garraway LA; Johannessen CM; Meyerson M
    Mol Cancer Res; 2019 Nov; 17(11):2281-2293. PubMed ID: 31462500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tyrosine Kinase Inhibitors Increase MCL1 Degradation and in Combination with BCLXL/BCL2 Inhibitors Drive Prostate Cancer Apoptosis.
    Arai S; Jonas O; Whitman MA; Corey E; Balk SP; Chen S
    Clin Cancer Res; 2018 Nov; 24(21):5458-5470. PubMed ID: 30021909
    [No Abstract]   [Full Text] [Related]  

  • 10. A small molecule inhibitor of the UBE2F-CRL5 axis induces apoptosis and radiosensitization in lung cancer.
    Xu T; Ma Q; Li Y; Yu Q; Pan P; Zheng Y; Li Z; Xiong X; Hou T; Yu B; Liu H; Sun Y
    Signal Transduct Target Ther; 2022 Oct; 7(1):354. PubMed ID: 36253371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting a mitochondrial E3 ubiquitin ligase complex to overcome AML cell-intrinsic Venetoclax resistance.
    Nakao F; Setoguchi K; Semba Y; Yamauchi T; Nogami J; Sasaki K; Imanaga H; Terasaki T; Miyazaki M; Hirabayashi S; Miyawaki K; Kikushige Y; Masuda T; Akashi K; Maeda T
    Leukemia; 2023 May; 37(5):1028-1038. PubMed ID: 36973350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gossypol inhibits cullin neddylation by targeting SAG-CUL5 and RBX1-CUL1 complexes.
    Yu Q; Hu Z; Shen Y; Jiang Y; Pan P; Hou T; Pan ZQ; Huang J; Sun Y
    Neoplasia; 2020 Apr; 22(4):179-191. PubMed ID: 32145688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Noxa upregulation and 5-gene apoptotic biomarker panel in colorectal cancer.
    Kosmidou V; Vlassi M; Anagiotos K; Raftopoulou S; Kalogerakou E; Skarmalioraki S; Aggeli C; Choreftaki T; Zografos G; Pintzas A
    Eur J Clin Invest; 2021 Jan; 51(1):e13353. PubMed ID: 32682341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MCL1 inhibition is effective against a subset of small-cell lung cancer with high MCL1 and low BCL-X
    Yasuda Y; Ozasa H; Kim YH; Yamazoe M; Ajimizu H; Yamamoto Funazo T; Nomizo T; Tsuji T; Yoshida H; Sakamori Y; Nakajima N; Menju T; Yoshizawa A; Date H; Hirai T
    Cell Death Dis; 2020 Mar; 11(3):177. PubMed ID: 32152266
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mcl-1 Phosphorylation without Degradation Mediates Sensitivity to HDAC Inhibitors by Liberating BH3-Only Proteins.
    Tong J; Zheng X; Tan X; Fletcher R; Nikolovska-Coleska Z; Yu J; Zhang L
    Cancer Res; 2018 Aug; 78(16):4704-4715. PubMed ID: 29895675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cullin-5 neddylation-mediated NOXA degradation is enhanced by PRDX1 oligomers in colorectal cancer.
    Xu S; Ma Y; Tong Q; Yang J; Liu J; Wang Y; Li G; Zeng J; Fang S; Li F; Xie X; Zhang J
    Cell Death Dis; 2021 Mar; 12(3):265. PubMed ID: 33712558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CDK9 inhibitors selectively target estrogen receptor-positive breast cancer cells through combined inhibition of MYB and MCL-1 expression.
    Mitra P; Yang RM; Sutton J; Ramsay RG; Gonda TJ
    Oncotarget; 2016 Feb; 7(8):9069-83. PubMed ID: 26812885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Involvement of MCL1, c-myc, and cyclin D2 protein degradation in ponatinib-induced cytotoxicity against T315I(+) Ph+leukemia cells.
    Inoue C; Sobue S; Kawamoto Y; Nishizawa Y; Ichihara M; Abe A; Hayakawa F; Suzuki M; Nozawa Y; Murate T
    Biochem Biophys Res Commun; 2020 May; 525(4):1074-1080. PubMed ID: 32184020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MARCH5 requires MTCH2 to coordinate proteasomal turnover of the MCL1:NOXA complex.
    Djajawi TM; Liu L; Gong JN; Huang AS; Luo MJ; Xu Z; Okamoto T; Call MJ; Huang DCS; van Delft MF
    Cell Death Differ; 2020 Aug; 27(8):2484-2499. PubMed ID: 32094511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy.
    Inoue-Yamauchi A; Jeng PS; Kim K; Chen HC; Han S; Ganesan YT; Ishizawa K; Jebiwott S; Dong Y; Pietanza MC; Hellmann MD; Kris MG; Hsieh JJ; Cheng EH
    Nat Commun; 2017 Jul; 8():16078. PubMed ID: 28714472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.